There’s Something Awry at Edwards Lifesciences Corp (NYSE:EW) Since Share Price Gets Ahead of Fundamentals

The stock of Edwards Lifesciences Corp (NYSE:EW) last traded at $75.49, down -1.04% from the previous session.

EW stock price is now 5.85% away from the 50-day moving average and 7.09% away from the 200-day moving average. The market capitalization of the company currently stands at $44.22B.

With the price target maintained at $80, Piper Sandler recently Upgraded its rating from Neutral to Overweight for Edwards Lifesciences Corp (NYSE: EW). On January 30, 2025, Stifel Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $75 to quote $90, while ‘Wolfe Research’ rates the stock as ‘Underperform’

In other news, BOBO DONALD E JR, CVP,Strategy/Corp Development sold 9,500 shares of the company’s stock on Apr 14 ’25. The stock was sold for $663,196 at an average price of $69.81. Upon completion of the transaction, the CVP,Strategy/Corp Development now directly owns 47,206 shares in the company, valued at $3.56 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 08 ’25, CVP, JAPAC Lippis Daniel J. sold 300 shares of the business’s stock. A total of $21,183 was realized by selling the stock at an average price of $70.61. This leaves the insider owning 22,863 shares of the company worth $1.73 million. A total of 1.95% of the company’s stock is owned by insiders.

During the past 12 months, Edwards Lifesciences Corp has had a low of $58.93 and a high of $95.25. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 4.18, and a quick ratio of 3.45. According to the stock market information, the enterprise value for the company is $41169170432, which is based on a 30.49 price-to-earnings ratio, a 3.57 price-to-earnings-growth ratio, and a beta of 1.12. The fifty day moving average price for EW is $71.3164 and a two-hundred day moving average price translates $70.48985 for the stock.

The latest earnings results from Edwards Lifesciences Corp (NYSE: EW) was released for 2025-03-31. The net profit margin was 26.60% and return on equity was 17.17% for EW. The company reported revenue of $1.1 billion for the quarter, compared to $1.01 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.85 percent.

Related Posts

Fosters Research
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.